Heparin in acute ischaemic stroke

Medical Journal of Australia

Volumn 169, Issue 10, 1998, Pages 534-536

  Hankey, Graeme J ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DANAPAROID; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL TRIAL; FIBRIN FORMATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBUS; TREATMENT OUTCOME;

EID: 0032539025     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1998.tb123401.x     Document Type: Article

References (19)

1. Asher R. Apriority. Thoughts on treatment. Lancet 1961; II: 1403-1404.
2. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574.
3. Chong BH. Heparin-induced thrombocytopenia. Aust N Z J Med 1992; 22: 145-152.
4. Schafer AI. Antiplatelet therapy. Am J Med 1996; 101: 199-209.
5. Topol EJ. Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998; 97: 211-218.
6. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989; 95: 2S-4S.
7. Marsh EE III, Adams HP Jr, Biller J, et al. Use of antithrombotic drugs in the treatment of acute ischaemic stroke. A survey of neurologists in practice in the United States. Neurology 1989; 29: 1631-1634.
8. Smith MA, Shahar E, Doliszny KM, et al. Trends in medical care of hospitalised stroke patients between 1980 and 1990: The Minnesota Stroke Survey. J Stroke Cerebrovasc Dis 1998; 7: 76-84.
9. Lindley RI, Amayo EO, Marshall J, et al. Acute stroke treatment in UK hospitals: The Stroke Association Survey of consultant opinion. J R Coll Physicians Lond 1995; 29: 479-484.
10. Sandercock P, van den Belt AGM, Lindley RI, Slattery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1993; 56: 17-25.
11. Weitz JI. Low-molecular-weight-heparins. N Engl J Med 1997; 337: 688-698
12. Kay R, Wong KS, Yu YL, Chan YW, et al. Low-molecular-weight heparin for the treatment of acute ischaemic stroke. N Engl J Med 1995; 333: 1588-1593.
13. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581.
14. Bousser M. Aspirin or heparin immediately after a stroke? Lancet 1997; 349: 1564-1565.
15. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischaemic stroke. A randomised controlled trial. JAMA 1998; 279: 1265-1272.
16. Hommel M for the FISS bis Investigators Group. Fraxiparine in Ischaemic Stroke Study (FISS bis) [abstract]. Cerebrovasc Dis 1998; 8 (Suppl 4): 19.
17. Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996; 313: 652-659.
18. Hachinski V. Vagus nerve stimulation therapy. Arch Neurol 1998; 55: 234.
19. Huxley TH. VIII Discourses: Biological and geological, biogenesis, and abiogenesis. In: Collected essays (1893-1894). New York, NY: Georg Olms Verlag Hildesheim; 1970: 244.